Physician profile
Fred N Thomas
NPI 1518958420
$4,960.25
in general payments reported to CMS, 2019-2025
34 companies · $487 in 2025
The $487 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $675 · 2020: $744 · 2021: $1,378 · 2022: $698 · 2023: $624 · 2024: $355 · 2025: $487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,466.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,465.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $724.10 | 2021-2025 | Ubrelvy, Qulipta |
| Novo Nordisk INC | $612.47 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $489.52 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $485.00 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $440.32 | 2019-2023 | Farxiga, Breztri |
| Pfizer INC. | $392.06 | 2019-2025 | |
| Lilly USA, LLC | $297.00 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Biohaven Pharmaceuticals, INC. | $208.11 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $196.01 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $187.16 | 2022 | |
| Amgen INC. | $130.36 | 2019-2025 | Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $71.13 | 2019-2025 | |
| Amarin Pharma, INC. | $60.50 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.50 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $53.44 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $51.31 | 2021 | |
| Novartis Pharmaceuticals Corporation | $47.75 | 2019-2023 | |
| Abbott Laboratories | $44.13 | 2021-2022 | |
| Esperion Therapeutics, INC. | $43.49 | 2020-2021 | |
| Dexcom, INC. | $37.28 | 2023-2024 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $36.86 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.62 | 2020-2021 | |
| Sanofi Pasteur INC. | $35.01 | 2022-2023 | |
| Horizon Therapeutics Plc | $34.69 | 2021-2023 | Krystexxa |
| Kowa Pharmaceuticals America, INC. | $30.26 | 2019-2020 | |
| Edwards Lifesciences Corporation | $27.65 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Avanir Pharmaceuticals, INC. | $27.31 | 2019 | |
| Exact Sciences Corporation | $16.89 | 2023 | Cologuard Collection Kit |
| Philips North America LLC | $15.81 | 2024 | (Ck6) Holter |
| Inspire Medical Systems, INC. | $15.15 | 2024 | Inspire |
| Upsher-Smith Laboratories LLC | $14.65 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $14.51 | 2020 | |
| Allergan, INC. | $13.29 | 2020 | |
| Kaleo, INC. | $11.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fred Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.